Synapse - Lindsey Roeker

Results (139)

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML

Meeting Abstract

Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
Blood (2024)

Fulltext@MSK | Save

Association between dose reduction and duration of therapy in patients receiving ibrutinib or acalabrutinib for chronic lymphocytic leukemia: A medical chart review study

Meeting Abstract

Shadman, M.; Roeker, L.; Pinilla-Ibarz, J.; Srivastava, B.; Karve, S.; Krigsfeld, G. S.; Franceschini, E.; Saifan, C.; Karanth, S.; Goyal, R. K.; more...
Blood (2024)

Fulltext@MSK | Save

Outcomes of therapies following discontinuation of non-covalent Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and Richter transformation: Results from an international, multicenter study

Meeting Abstract

Thompson, M. C.; Bhat, S. A.; Jurczak, W.; Patel, K.; Shah, N. N.; Woyach, J. A.; Coombs, C. C.; Eyre, T. A.; Danecki, M.; Dlugosz-Danecka, M.; more...
Blood (2024)

Fulltext@MSK | Save

Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)

Meeting Abstract

Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
Blood (2024)

Fulltext@MSK | Save

Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)

Meeting Abstract

Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
Blood (2024)

Fulltext@MSK | Save

BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Meeting Abstract

Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Mátrai, Z.; Sanna, A.; more...
Blood (2024)

Fulltext@MSK | Save

Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs BTKi therapies in 1L CLL: An international real-world study

Meeting Abstract

Lamanna, N.; Brown, J. R.; Ujjani, C. S.; Eyre, T. A.; Manzoor, B.; Ghosh, N.; Roeker, L.; Davids, M. S.; Coombs, C. C.; Skarbnik, A. P.; more...
Blood (2024)

Fulltext@MSK | Save

Efficacy of pirtobrutinib in BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Phase 1/2 BRUIN study results by prior BCL2-inhibitor therapy

Meeting Abstract

Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
Oncology Research and Treatment (2024)

Fulltext@MSK | Save

Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study

Meeting Abstract

Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
Oncology Research and Treatment (2024)

Fulltext@MSK | Save

Pirtobrutinib in heavily pre-treated richter transformation: Updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN study

Meeting Abstract

Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffman, M. S.; Coombs, C. C.; Lamanna, N.; Shuo, M. A.; Jagadeesh, D.; Munir, T.; more...
Oncology Research and Treatment (2024)

Fulltext@MSK | Save

Lindsey Elizabeth Roeker

Results (139)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract